Literature DB >> 24032977

Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.

Pier Luigi Zinzani1, Enrico Derenzini, Cinzia Pellegrini, Monica Celli, Alessandro Broccoli, Lisa Argnani.   

Abstract

Entities:  

Keywords:  Hodgkin lymphoma; bendamustine; brentuximab vedotin; refractory; relapsed

Mesh：

Substances：

Year:  2013        PMID： 24032977     DOI： 10.1111/bjh.12548

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

Review 1.  Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.

Authors:  Liana Nikolaenko; Robert Chen; Alex F Herrera
Journal:  Ther Adv Hematol       Date:  2017-08-29

Review 2.  Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review.

Authors:  Roberta Fedele; Massimo Martino; Anna Grazia Recchia; Giuseppe Irrera; Massimo Gentile; Fortunato Morabito
Journal:  J Immunol Res       Date:  2015-12-16       Impact factor: 4.818

3.  Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review.

Authors:  Vivek S Radhakrishnan; Rajat Bajaj; Vasundhara Raina; Jeevan Kumar; Saurabh J Bhave; Reghu K Sukumaran Nair; Arijit Nag; Indu Arun; Lateef Zameer; Debdeep Dey; Neeraj Arora; Mayur Parihar; Jayanta Das; Rimpa B Achari; Deepak K Mishra; Mammen Chandy; Reena Nair
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

Review 4.  Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Authors:  Bruce D Cheson; Wolfram Brugger; Gandhi Damaj; Martin Dreyling; Brad Kahl; Eva Kimby; Michinori Ogura; Eckhart Weidmann; Clemens-Martin Wendtner; Pier Luigi Zinzani
Journal:  Leuk Lymphoma       Date:  2015-11-23

Review 5.  Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective.

Authors:  Anna Sureda; Marc André; Peter Borchmann; Maria G da Silva; Christian Gisselbrecht; Theodoros P Vassilakopoulos; Pier Luigi Zinzani; Jan Walewski
Journal:  BMC Cancer       Date:  2020-11-10       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.